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Abstract
Objective Statins pleiotropically provide additional benefits in reducing atherosclerosis, but their effects on intraplaque 
angiogenesis (IPA) and hemorrhage (IPH) remain unclear. Therefore, we discriminated statin’s lipid-lowering dependent 
and independent effects on IPA and IPH.
Approach and results ApoE3*Leiden mice are statin-responsive due to ApoE and LDLR presence, but also allow to titrate 
plasma cholesterol levels by diet. Therefore, ApoE3*Leiden mice were fed a high-cholesterol-inducing-diet (HCD) with 
or without atorvastatin (A) or a moderate-cholesterol-inducing-diet (MCD). Mice underwent vein graft surgery to induce 
lesions with IPA and IPH. Cholesterol levels were significantly reduced in MCD (56%) and HCD + A (39%) compared to 
HCD with no significant differences between MCD and HCD + A. Both MCD and HCD + A have a similar reduction in vessel 
remodeling and inflammation comparing to HCD. IPA was significantly decreased by 30% in HCD + A compared to HCD or 
MCD. Atorvastatin treatment reduced the presence of immature vessels by 34% vs. HCD and by 25% vs. MCD, resulting in 
a significant reduction of IPH. Atorvastatin’s anti-angiogenic capacity was further illustrated by a dose-dependent reduction 
of ECs proliferation and migration. Cultured mouse aortic-segments lost sprouting capacity upon atorvastatin treatment and 
became 30% richer in VE-Cadherin expression and pericyte coverage. Moreover, Atorvastatin inhibited ANGPT2 release 
and decreased VE-Cadherin(Y685)-phosphorylation in ECs.
Conclusions Atorvastatin has beneficial effects on vessel remodeling due to its lipid-lowering capacity. Atorvastatin has 
strong pleiotropic effects on IPA by decreasing the number of neovessels and on IPH by increasing vessel maturation. Atorv-
astatin improves vessel maturation by inhibiting ANGPT2 release and phospho(Y658)-mediated VE-Cadherin internalization.
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Statins are currently the principal drug in primary and 
secondary prevention of coronary artery disease [1]. As 
HMG-CoA-reductase inhibitors, they improve the human 
lipid profile and decrease atherosclerosis progression by 
lowering the low-density lipids (LDL) plasma levels [2, 
3]. Interestingly, the observed benefits of statin treatment 
appear to be greater than what might be expected from 
changes in lipid levels alone, suggesting effects beyond 
cholesterol lowering. Indeed, many studies demonstrated 
that statins can pleiotropically improve endothelial cell 
(EC) function [4–7] and inflammation [8, 9], providing 
an additional benefit in the reduction of atherosclerosis 
[10–13].
Atherosclerotic plaques can grow to such dimensions 
that the core becomes hypoxic and intraplaque angiogen-
esis (IPA) is induced [14]. Angiogenesis, the physiological 
response to restore oxygen levels is a consistent feature 
of atherosclerotic plaque development [15]. Due to the 
growth of the intimal layer and the increased amount of 
metabolically active inflammatory cells in advance lesions, 
oxygen is consumed at a very high rate, triggering hypoxia 
inducible factor (HIF)1α activity and the expression of 
vascular endothelium growth factor (VEGF)A [16]. Con-
sequently, ECs proliferate and migrate to form neovessel-
like structures and overcome the oxygen demand in the 
plaque. However, these neovessels frequently have an 
immature nature, characterized by a discontinuous base-
ment membrane, a lack of EC junctions and poor pericyte 
coverage [17]. Immature neovessels are highly suscepti-
ble to leakage of blood, resulting in intraplaque haemor-
rhage (IPH) [18]. Extravasated red blood cells are the main 
components of IPH and play a major role in cholesterol 
accumulation and monocyte recruitment into the plaque, 
initiating a vicious cycle that leads to further plaque desta-
bilization [19].
Neovessel maturation is mainly regulated by the angi-
opoietin (ANGPT)1/2–Tie2 cascade [20, 21] ANGPT1 is 
an agonist of the Tie2 receptor and promotes the endothe-
lial barrier function, by stimulating VE-Cadherin (VE-Cad) 
junctional accumulation in ECs and pericytes recruitment 
[22–26]. In hypoxia, ANGPT2 is rapidly released from EC’s 
Weibel–Palade bodies [27]. Excess of ANGPT2 antagonizes 
ANGPT1 [21], and inhibits Tie2 downstream signaling in 
pericytes and ECs, culminating in a phospho-dependent 
internalization of VE-Cad and pericyte recruitment inhibi-
tion [28]. Whereas ANGPT1 stabilizes vessels when angio-
genesis is completed, ANGPT2 destabilizes the vasculature 
to potentiate VEGFA triggered angiogenesis [29].
In recent years, a growing number of studies has sug-
gested that statins can exert anti-angiogenic effects and 
improve IPA [30–32]. It was shown that statins reduce 
adventitial neovascularisation in an  ApoE−/− mouse model 
[11], and IPA in the  ApoE−/−Fbn1C1039G+/− mouse model 
[12]. However, as observed in many other  ApoE−/− mouse 
models, the effects seen were not related to the choles-
terol lowering capacity of statins since these strains are 
unable to respond to statins. In addition, in a clinical set-
ting, it was reported that patients treated with atorvastatin 
present less IPA compared to non-treated patients [33]. 
However, for those reported effects, it could not be dis-
criminated whether they were lipid-lowering dependent 
or independent. Therefore, the extent of a potent benefit 
of the pleiotropic effects of statin therapy in IPA and IPH 
still remains to be determined and especially the molecular 
mechanism(s) behind it.
Mouse models commonly used to study atherosclerosis 
are deficient in LDLR or ApoE, both crucial proteins in LDL 
clearance. Their absence makes it impossible for statins to 
rescue LDL from the blood, since the inhibition of HMG-
CoA reductase (the mode of action of statins) does not occur. 
As a result of the inhibition of the intracellular synthesis 
also the uptake of LDL in the blood fails in  ApoE−/− and 
 LDLR−/− mice. Thus, no changes in blood lipid levels are 
found in  ApoE−/− and  LDLR−/−mice upon statin treatment. 
Additionally, spontaneous murine atherosclerotic lesions are 
hardly suitable to study IPA. Due to their small size lesions, 
no ischemia occurs, resulting in none to minimal neovessels 
infiltration. To overcome these issues, we used hypercho-
lesterolemic ApoE*Leiden mice and the vein graft model 
to study the pleiotropic effects of statins on IPA and IPH. 
ApoE3*Leiden mice are a transgenic strain that contains the 
human ApoE3*Leiden gene and develops hyperlipidaemia due 
to the defective binding of ApoE3*Leiden to the LDLR [34, 
35]. This mutation makes it possible to create a diet-induced 
human like atherosclerotic plaque while these mice keep the 
sensitivity to statins due to the presence of ApoE and LDLR. 
Moreover, as we previously reported, the vein graft model pre-
sents plaque components that highly resembles human plaque 
features, including ischemia, plaque angiogenesis and leaky 
neovessels [36].
In this study, we demonstrate both, the lipid lowering-
dependent and independent effects of atorvastatin on vein 
graft atherosclerosis, including IPA and IPH. We also present 
evidence of the pathophysiological and molecular mechanism 
of atorvastatin-mediated inhibition on neovascularization.
Material and methods
Animals
All animal experiments were performed in compli-
ance with the Animal Welfare Committee of the Leiden 
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Medical University Center (project number: 13064) and 
the Directive 2010/63/EU of the European Parliament. 
Male ApoE3*Leiden mice, crossbred in our own colony 
on a C57BL/6 background for at least 40 generations, 
10–16 weeks old, were allocated randomly to three groups. 
One group was fed with a moderate-cholesterol inducing 
diet (Diet W: 1% cholesterol and 0.1% cholate w/w, AB 
diets)—MCD group—and the other two with a high-cho-
lesterol inducing diet (Diet N: containing 1% cholesterol 
and 0.1% cholate w/w, AB diets) with and without atorvas-
tatin (2.8 mg/kg/day)—HCD + A and HCD groups, respec-
tively—during all the experiment. Food and water were 
provided ad libitum and the mice were housed on regular 
bedding and nesting material.
Vein graft surgery
After three weeks on respective diets, the mice underwent 
vein graft surgery, in which a donor caval vein, derived from 
a non-transgenic litter, was placed as an interposition in the 
carotid artery of recipient mice, as described before [36]. 
Mice were anesthetized via intraperitoneal injection of 5 mg/
kg midazolam (Roche Diagnostics), 0.5 mg/kg medetomi-
dine (Orion Corporation) and 0.05 mg/kg fentanyl (Jans-
sen Pharmaceutical). After the surgery, the anaesthesia was 
antagonized with 2.5 mg/kg atipamezol (Orion Corporation) 
and 0.5 mg/kg fluminasenil (0.5 mg/kg, Fresenius Kabi). 
0.1 mg/kg buprenorphine (MSD Animal Health, Nether-
lands) was given for pain relieve. On the day of sacrifice 
mice underwent deep anesthesia and were euthanized by 
exsanguination, followed by 3 min of in vivo perfusion-
fixation with PBS and 4% formaldehyde (100,496, Sigma-
Aldrich). The vein grafts were harvested and fixed in 4% 
formaldehyde. Blood samples were collected and plasma 
cholesterol levels of all mice were determined before and 
28  days after the vein graft surgery (1,489,437, Roche 
Diagnostics).
Histological analysis of the vein grafts
Vein graft samples were embedded in paraffin and sequen-
tial cross Sections (5 µm thick) were taken from the entire 
length of the cuffed vein. For each mouse, six equal spaced 
cross-sections over the total vein graft length were used for 
analysis.
To assess vein graft remodeling morphometry was per-
formed on the cross sections. For this, the vein graft area 
surrounded by the adventitia (Vessel Area), the area of the 
lumen (Lumen Area) and Vessel Wall Area (subtraction of the 
last two) were measured in Hematoxilin–Phloxin–Saphron 
stained sections.
To assess vein graft morphology, the amount of collagen 
(% Collagen), by staining for Sirius Red, and the presence 
of vascular smooth muscle cells (% VSMCs) and mac-
rophages (% Macrophages), by immunohistochemistry for 
alpha smooth muscle actin (αSMA, 1A4 Dako) and Mac-3 
(553,322, BD Pharmingen), were quantified.
To assess intraplaque angiogenesis and intraplaque hem-
orrhage, a combined immunofluorescence staining was per-
formed for CD31 (sc-1506-r, Santa Cruz, Biotechnology), 
to detect neovessels, for αSMA, to evaluate vessel matura-
tion, and for TER119 (116,202, Biolegend) to rate endothe-
lium leakage. CD31 + neovessels structures were manually 
counted (% Neovessels) and the percentage of neovessel 
CD31 + αSMA- was defined as % Immature Neovessels. 
Intraplaque Hemorrhage was regionally assessed using a 
scoring system accounting for the presence and the num-
ber of erythrocytes outside the neovessels. No presence was 
scored as 0, low number of erythrocytes outside the neoves-
sels (1–10) was score as 1, intermediate number (11–30) as 
2, high number (> 30) as 3.
For each antibody, an isotype-matched was used as a 
negative control. The measured immuno-positive area is 
expressed as a percentage of the Vessel Wall Area. Pictures 
were acquired with the Pannoramic SCAN II (3DHistech) 
and analyzed with QWIN software (Leica).
Cell culture
For the isolation of HUVECS anonymous umbilical cords 
were obtained in accordance with guidelines set out by the 
‘Code for Proper Secondary Use of Human Tissue’ of the 
Dutch Federation of Biomedical Scientific Societies (Fed-
era), and conform to the principles outlined in the Decla-
ration of Helsinki. Human umbilical vein endothelial cells 
(HUVEC) were isolated and cultured as described by Wel-
ten et al. [37]. In brief, the vein in the umbilical cords was 
flushed with PBS and incubated with 0.75 mg/mL colla-
genase type II (LS004177, Worthington Biochemical Cor-
poration) for 20 min at 37 °C. Detached ECs were washed 
out of the vessel and left to grow in complete medium 
[EBM-2 medium (00,190,860) supplemented with EGM 
BulletKit (CC-3124, Lonza) and 2% of FBS (10,082,139, 
ThermoFisher Scientific)] at 37 °C in a 5%  CO2 humidified 
incubator. Culture medium was refreshed every 2–3 days. 
Cells were passed using trypsin–EDTA (T4049, Sigma-
Aldrich) at 90–100% confluency. HUVECs were used up to 
passage three for proliferation and migration assays, and up 
to passage seven for protein expression analysis by western 
blotting.
Metabolic assay
Cell metabolism was measured by the reduction of 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, M5655, Sigma-Aldrich). HUVECs were 
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seeded in 96-wells plate in complete medium and grown 
until 80% confluency. To cause cell cycle arrest, cells 
were incubated for 24 h in EBM-2 medium supplemented 
with 0.2% FBS. Atorvastatin was added in a concentration 
range of 0.05 µg/ml, 0.5 µg/ml until 5 µg/ml. After 18 h, 
cells were incubated with MTT for 4 h. A supernatant frac-
tion was replaced by 0.01 N HCL-isopropanol (258,148 
and 563,935, Sigma-Aldrich) and absorbance was meas-
ured at 570 nm by Cytation™ 5 Cell Imaging Multi-Mode 
Reader (BioTek Instruments).
Migration assay
For migration assays, HUVECs were seeded in 12-wells 
plate in complete medium and grown until 80% conflu-
ence. To cause cell cycle arrest, cells were incubated in 
EBM-2 medium supplemented with 0.2% FBS and 24 h 
later, a scratch-wound was made. Atorvastatin was added 
in a concentration range of 0.05 µg/ml, 0.5 µg/ml until 
5 µg/ml. Three locations along the scratch-wound were 
marked per well and scratch-wound closure at these sites 
was imaged at time 0 and 18 h by using an Axiovert 40c 
Inverted & Phase Contrast Microscope (451,207, Carl 
Zeiss). Average scratch-wound closure was calculated by 
measuring cell coverage at 18 h vs 0 h using ImageJ.
Aortic ring sprouting assay
The aortic ring assay was performed as described previ-
ously.[37–39] Three ApoE3*Leiden mice, 4–8 weeks old, 
were anesthetized and the aorta was dissected. Each aorta 
was cut in 1 mm rings, and serum-starved in Gibco™ 
Opti-MEM™ GlutaMAX (51,985,034, ThermoFisher 
Scientific) overnight at 37  °C and 5% CO2. On the 
next day, each ring was mounted in a well of a 96-well 
plate in 70  µl of 1.0  mg/ml acid-solubilized collagen 
type-I (11,179,179,001, Roche Diagnostics) in DMEM 
(12,634,010, ThermoFisher Scientific). After collagen 
polymerization, Gibco™ Opti-MEM™ GlutaMAX sup-
plemented with 2.5% FCS and 30 ng/ml VEGF (293-VE, 
R&D systems) was added with atorvastatin (0.05 µg/ml, 
0.5 µg/ml and 5 µg/ml). The rings were cultured for 7 days 
and photographed by using an Axiovert 40c microscope. 
The number of sprouts were counted manually. For immu-
nohistochemistry, rings were formalin-fixed and permea-
bilized with 0.2% Triton X-100 (11,332,481,001, Merck). 
Rings were stained with αSMA, CD31 and VE-Cadherin 
(AF1002, R&D Systems). Extended focus pictures were 
made with the Pannoramic SCAN II and quantified with 
Image J.
Protein expression analysis by western blotting
HUVECs (80% confluent) were treated overnight with 
increasing doses of atorvastatin (0.05 µg/ml, 0.5 µg/ml and 
5 µg/ml) in EBM-2 medium with 0.2% FBS and stimulated 
for 30 min with 50 ng/ml of PMA.
Medium was collected for TCA-precipitation [40] 
and cells were scraped in RIPA buffer [10 mM Tris–HCl 
pH = 7.4, 150 mM NaCl, 5 mM EDTA pH = 8.0, 1% Tri-
ton X-100, 1% SDS, with freshly added 1 mM NaF, 1 mM 
Na3VO4 and cOmplete™ Protease Inhibitor Cocktail 
(1,169,749,800, Roche Diagnostics)]. Total protein concen-
tration was quantified by Pierce™ BCA Protein Assay Kit 
(23,225, ThermoFisher Scientific). 15 µg of protein were 
separated by SDS-PAGE in a 4–15% minigel and transferred 
into a nitrocellulose membrane. Blots were incubated with 
pY685-VE-Cadherin (ab119785, Abcam); VE-Cadherin 
(MA1-198, ThermoFisher), pY992-Tie2 ((4221S, Cell Sign-
aling Technology); Tie2 (4224S, Cell Signaling Technol-
ogy); pY418-Src (ab4816, Abcam); Src (2110, Cell Signal-
ing Technology); ANGPT2 (ab155106, Abcam)) overnight 
at 4ºC. A suitable peroxidase conjugated secondary antibody 
was used (31,462, 31,432, 31,400, ThermoFisher Scientific). 
Proteins of interest were imaged with SuperSignal™ West 
Pico PLUS Chemiluminescent Substrate (34,580, Ther-
moFisher Scientific) and the ChemiDoc™ Touch Imaging 
using System (1,708,370, Bio-Rad Laboratories). β-actin 
(ab8220, Abcam) was used as internal control and blots were 
quantified with Image J.
Statistical analysis
All data are presented as mean ± standard error of the mean 
(SEM). Normality was determined using the Shapiro–Wilk 
normality test. Overall comparisons between groups were 
performed using 1-way ANOVA on parametric data using 
the statistics software GraphPad Prism 8.02. p values less 
than 0.05 were regarded as statistically significant.
Results
Atorvastatin decreases cholesterol levels 
in ApoE3*Leiden mice
To evaluate the cholesterol levels in ApoE3*Leiden mice on 
a moderate-cholesterol inducing diet (MCD) and on a high-
cholesterol inducing diet (HCD) with or without atorvasta-
tin (A), we measured the plasma cholesterol levels one day 
before vein graft surgery (Fig. 1a) and 28 days after surgery, 
at terminal day (Fig. 1b).
At both time points, we observed a comparable degree 
of cholesterol lowering. At day 1, the plasma cholesterol 
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levels were in the MCD (by 49%, p = 0.0006) and in the 
HCD + A (by 32%, p = 0.0190) groups in comparison to 
the HCD group. At day 28, those plasma cholesterol levels 
were further decreased in the MCD (by 56%, p < 0.0001) 
and HCD + A (by 39%, p = 0.0035) groups, respectively, 
in comparison to the HCD group. At both time points, no 
Fig. 1  Atorvastatin reduces cholesterol levels and vein graft thicken-
ing in ApoE3*Leiden mice. Cholesterol levels one day before surgery 
(a) and at day of sacrifice (b). Quantitative measurements of Vessel 
Area (c), Vessel Wall Area (d) and Lumen Area (e). Representa-
tive vein grafts cross sections of an Haematoxylin–Phloxine–Saf-
fron staining in HCD (n = 6), MCD (n = 8) and HCD + A (n = 6) (f). 
Data presented as mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001 by 1-way ANOVA
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significant differences were observed between the MCD and 
HCD + A groups.
Therefore, these ApoE3*Leiden mice can be used to 
study the pleiotropic effects of atorvastatin on vein graft 
lesions, an accelerated form of atherosclerosis, by compar-
ing the effects of atorvastatin in the HCD + A group with the 
effects of lipid lowering alone, as is observed in the MCD 
group.
Atorvastatin decreases vein graft thickening
To assess vein graft lesion morphometry, we measured Ves-
sel Area, Vessel Wall Area and Lumen Area as represented 
in Fig. 1.
Both, MCD and HCD + A groups, show a decrease in Ves-
sel Area in comparison to HCD group, by 29% (p = 0.0361) 
and 33% (p = 0.0346), respectively (Fig. 1c and f). Atorv-
astatin treatment resulted in a comparable Vessel Area to 
the MCD group. Both MCD and HCD + A groups revealed 
a decrease in Vessel Wall Area in comparison with HCD 
group, 35% (p = 0.0430) and 34% (p = 0.0693), respectively 
(Fig. 1d and f). Whilst, no significant differences between 
MCD and HCD + A groups were observed. The Lumen Area 
was similar in all groups (Fig. 1e and f).
Since no differences were observed between HCD + A 
and MCD groups, and both exhibited similar cholesterol 
profiles, the observed effects on vein graft remodeling, as 
detected by morphometry, were most likely due to the lipid-
lowering effects of atorvastatin.
Atorvastatin decreases inflammation
To assess plaque morphology, we evaluated lesion inflam-
mation by determining the percentage (%) Macrophages and 
lesion stability by determining the % VSMCs and % Col-
lagen in the vessel wall (Fig. 2).
The % Macrophages was lower in the MCD (by 45%, 
p = 0.0013) and in the HCD + A (by 36%, p = 0.0142) groups 
in comparison to the HCD group (Fig. 1a and d). Atorv-
astatin-treated group had a comparable % Macrophages as 
the MCD group. The % Collagen did not vary between the 
groups (Fig. 2b and d). Both MCD and HFD + A groups 
exhibited a highly significant decrease in the % VSMCs 
compared with the HCD group, 56% (p = 0.0007) and 67% 
(p = 0.0004), respectively, but the MCD and HCD + A 
groups had similar % VSMCs values (Fig. 2c and d).
Since % Macrophages and % VSMCs were equal in the 
HCD + A and MCD, and both groups had comparable cho-
lesterol profiles, this decrease in macrophages and VSMCs 
in vein graft lesions could again be attributed to the lipid-
lowering effect of atorvastatin.
Atorvastatin decreases plaque neovessel density, 
increases vessel maturity, improving intraplaque 
hemorrhage in vivo
To evaluate intraplaque angiogenesis and intraplaque hemor-
rhage, we measured % Neovessels, % Immature Neovessels 
and scored Intraplaque Hemorrhage in the vein graft lesions 
(Fig. 3).
The % Neovessels was decreased by 30% in atorvastatin-
treated group, when compared with the HCD (p = 0.0472) 
and MCD (p = 0.0395) groups, as shown in Fig. 3a. The HCD 
and MCD groups presented similar % Neovessels values. For 
studying (im)maturity of the neovessels, we determined the 
coverage of the neovessels by pericytes. In Fig. 3f, we revealed 
that neovessels (CD31, in orange) from plaques treated with 
atorvastatin were surrounded by a more continuous pericyte 
coverage (αSMA, in green) when compared with the other 
groups.
Quantification of % Immature vessels (Fig. 3c) showed a 
decrease in atorvastatin-treated group, when compared with 
the HCD (by 34%, p = 0.0002) and MCD (by 25%, p = 0.0066), 
with no differences between the last two groups.
We also observed that neovessels that were partly devoid 
of pericyte coverage were more prone to leakage of the eryth-
rocytes (Ter199, in red) in Fig. 3d. Accordingly, Intraplaque 
Hemorrhage was less present and less severe in the atorvas-
tatin-treated group when compared with the HCD and MCD 
(p = 0.0455) groups (Fig. 3d).
Taken together, our findings suggest that atorvastatin 
reduces intraplaque angiogenesis and intraplaque hemorrhage 
independent of its lipid lowering effects in vivo.
Atorvastatin decreases EC proliferation 
and migration in vitro
To confirm the pleiotropic effect of atorvastatin on intraplaque 
angiogenesis, we studied the effects of increasing doses of 
atorvastatin (0.05 µg/ml, 0.5 µg/ml and 5 µg/ml) on the capac-
ity of HUVECs to proliferate and migrate.
ECs proliferation (Fig. 4a) was significantly decreased by 
26% in 5 µg/ml dose of atorvastatin (p = 0.0197).
Regarding ECs migration (Fig. 4b and c), the ability of 
wound closure was dose-dependently decreased by atorvasta-
tin when compared to control, with significant effects at 0.5 µg/
ml (32% reduction, p = 0.0453) and 5 µg/ml (35% reduction, 
p = 0.0299).




Fig. 2  Atorvastatin increases plaque stability in ApoE3*Leiden 
mice. Quantitative measurements of % Macrophages (a), % Collagen 
(b) and % VSMCs (c). Representative vein grafts cross sections of 
Mac3, Sirus Red and αSMA stainings of HCD (n = 6), MCD (n = 8) 
and HCD + A (n = 6) group (d). Data presented as mean ± SEM. 
*p ≤ 0.05, ***p ≤ 0.001 by 1-way ANOVA
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Atorvastatin decreases sprouting while increases 
VE‑Cad expression and pericyte coverage
To study the pleiotropic effects of atorvastatin on neoves-
sel sprouting, we cultured mouse aortic segments ex vivo 
with increasing doses of atorvastatin: 0.05 µg/ml, 0.5 µg/
ml and 5 µg/ml (Fig. 5). The number of sprouts formed 
was decreased dose-dependently by atorvastatin when 
compared to the control group, with a 5-fold decrease for 
5 µg/ml (p = 0.0150) treated segments (Fig. 5a, d, f, h).
Next, we performed, on the same aortic segments, a tri-
ple staining for CD31, αSMA and VE-Cad to assess vessel 
maturation (Fig. 5e, g, f). In concordance with the previous 
quantification (Fig. 5a), we observed less CD31 + sprouts in 
the treated groups compared to the control group (Fig. 5e, 
g, i). Additionally, we determined that sprouts has increased 
VE-Cad levels when treated with atorvastatin (Fig. 5E1-3, 
G1-3, I1-3).
Quantification of VE-Cad expression revealed a dose-
dependently increase in expression by atorvastatin, in 
Fig. 3  Atorvastatin reduces plaque neovessels density and vessel 
immaturity, decreasing intraplaque haemorrhage in  vivo. Quanti-
tative measurements of % CD31+ Neovessels (a) and % Immature 
Neovessels (b) and Intraplaque Haemorrhage scoring (c). Repre-
sentative vein grafts cross sections of CD31 (orange), αSMA (green), 
TER119 (red) and DAPI (blue) staining in HCD (n = 6), MCD (n = 8) 
and HCD + A (n = 6) groups (d). Data presented as mean ± SEM. 
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 by 1-way ANOVA
Angiogenesis 
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comparison to the control group, with significant effects at 
5 µg/ml (27%, p = 0.0017). In parallel, as the concentration 
of atorvastatin increased, αSMA + cells along the sprouts 
were more abundant and organized (Fig. 5E4, G4, I4).
Quantification of our data revealed that αSMA+ cell pres-
ence significantly increased when treated with 0.5 µg/ml (by 
26%, p = 0.0187) and 5 µg/ml (by 29%, p = 0.0112) of atorv-
astatin, compared to the control group (Fig. 5c). In summary, 
atorvastatin not only decreased vessel sprouting, but also 
increased vessel maturation ex vivo.
Atorvastatin increases vessel maturation, 
by inhibiting ANGPT2 release and decreasing 
VE‑Cad(Y658)‑phosphorylation
To elucidate the molecular mechanism(s) on vessel matu-
ration, we investigated the effects of atorvastatin on the 
ANGTP1/2-TIE2 signaling pathway.
Unstimulated cells released low levels of ANGPT2, how-
ever, upon stimulation with PMA [27, 41, 42], ANGPT2 
levels in the medium increased significantly (Fig. 6a and 
c). Such release was lowered, in a dose–response manner, 
reaching basal levels at 5 µg/ml of atorvastatin (p = 0.009). 
When studying the activation of the Tie2 receptor by quan-
tifying its Y992 phosphorylation, we observed that 5 µg/
ml atorvastatin dose completely restored phosphorylation 
of the receptor. In fact, ANGPT2 and Y992-Tie2 levels were 
inversely correlated, suggesting that atorvastatin restores 
Tie2 phosphorylation by preventing ANGPT2 release.
Next, we assessed VE-Cad endocytosis by quantifying 
the phosphorylation of Y418 of Src and Y685 of VE-Cad. 
As predicted, inhibition of the Tie2 receptor (by ANGPT2 
release) induced Src and VE-Cad phosphorylation 
(Fig. 6d, e, c). These phosphorylations were decreased in 
a dose-dependent manner, by atorvastatin, reaching basal 
levels at 5 µg/ml, for both proteins (Src-Y418: p = 0.0003; 
VE-Cad-Y685: p = 0.0317). These findings suggest that 
Fig. 4  Atorvastatin reduces EC proliferation and migration in  vitro. 
Quantification of Atorvastatin effects on MMT assay (a) and on 
scratch wound healing assay (b) and representative images of wounds 
treated with increasing doses of Atorvastatin and control (c), 18  h 
after scratching. Data normalized to CTRL group (indicated as 1 by a 
dashed grey line in the graphs) and presented as mean ± SEM (n = 3). 
*p < 0.05, **p < 0.01; by 1-way ANOVA (* (in grey) are significances 
vs CTRL; * (in black) are significances between groups)
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atorvastatin is able to prevent VE-Cad internalization by 
decreasing its Src-dependent phosphorylation.
Taken together, our results suggest a mechanism by 
which atorvastatin increases vessel maturation, by inhib-
iting ANGPT2 release, a vascular-destabilizing factor, 
and decreasing VE-Cad Y658-phosphorylation, a key EC 
junction.
Discussion
In the current study, we demonstrated that atorvastatin has 
a beneficial effect on atherosclerotic plaque stability in 
hypercholesterolemic ApoE3*Leiden vein grafts due to 
its lipid lowering capacity. Furthermore, we demonstrated 
Fig. 5  Atorvastatin reduces sprout formation while improves vessel 
maturation by increasing VE-Cadherin expression ex  vivo. Quan-
tification of the Number of Sprouts after treatment with increas-
ing doses of Atorvastatin and VEFG (30  ng/ml) and control group 
treated only with VEGFA (30 ng/ml) in an ex vivo aortic ring assay 
(a). Phase-contrast representative images of aortic rings show-
ing microvessel outgrowth (d). Data is presented as mean ± SEM 
of 15 aortic segments per treatment, which were cut from aortas of 
three different mice. Quantification of % VE-Cad (b) and % αSMA 
(c) along the sprout. Representative examples (d) of extended focus 
scanner images of the aortic ring sprouts fluorescently stained for: 
CD31 (green) stains endothelial cells; VE-Cad (pink); α-SMA 
(red) stains smooth muscle cells and DAPI (blue). Data presented as 
mean ± SEM (n = 3). *p < 0.05, **p < 0.01; by 1-way ANOVA
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that atorvastatin has strong pleiotropic effects not only on 
IPA by reducing the number of intraplaque neovessels but 
also on IPH by increasing vessel maturation. As a mech-
anism, we provided evidences that atorvastatin affects 
neovessel stabilization by increasing pericyte coverage and 
EC junctions presence. We demonstrated that atorvastatin 
inhibits ANGPT2 release (a vascular-destabilizing factor), 
restoring Tie2-receptor activation (the main receptor in 
vessel maturation) and decreasing VE-Cad Y658-phospho-
rylation (a key EC junction).
Remodeling of the vessel wall is a crucial process in the 
development of atherosclerotic lesions in vein grafts [43]. 
During the adaptation of the venous segment to the arte-
rial blood pressure, VSMCs from the media proliferate 
and migrate leading to the growth of the intimal layer. In 
this study, we observed that atorvastatin treatment reduces 
outward remodeling or vessel area and lesion size or ves-
sel wall area when compared to the HCD group, while no 
differences in lumen area were found between the groups. 
Similar effects were observed between the MCD and HCD 
group. Because HCD + A and MCD groups exhibited equal 
cholesterol levels, the decrease in outward remodeling and 
lesion size could thus be attributed to atorvastatin mediated 
cholesterol lowering dependent effects. This is in con-
cordance with other studies that demonstrated that statins 
decrease intimal hyperplasia [11, 44, 45]. Changes in the 
plaque composition such as a reduction in the percentage 
of macrophages and VSMCs were observed to the same 
extend in the HCD + A and MCD group, when compared to 
the HCD. Since these effects were observed in both groups, 
these effects are cholesterol dependent. Macrophages are 
important in vein graft remodeling and vein graft plaque 
stability especially via their secretion of chemokines [43]. 
Therefore, decrease in macrophage content, which has been 
also reported by others as a statin-mediated effect [12, 46], 
contributes to plaque stability.
In this study, we demonstrate that atorvastatin decreases 
IPA in ApoE3*Leiden mice. This finding is documented in 
a set-up where ApoE3*Leiden mice cholesterol levels were 
not only significantly lowered upon atorvastatin treatment, 
but at a similar level as the MCD control group. Therefore, 
we were able to study statins’ cholesterol-independent 
effects in a clinically relevant way. Vein graft lesions treated 
with atorvastatin showed significantly less  CD31+ neoves-
sels not only when compared with the HCD group but, more 
importantly, also compared to the MCD group. Furthermore, 
Fig. 6  Atorvastatin increases vessel maturation by inhibiting 
ANGPT2 release. Quantification of ANGPT2 levels in medium (a) of 
HUVECs monolayers, treated overnight with Atorvastatin (0.05, 0.5 
or 5 µg/ml) and stimulated with PMA (50 ng/ml) for 30 min. Quan-
tification of phospho TIE2 (b) VE-Cad (d) an Src (e) relative to their 
total levels in the cell lysates. Representative experiment is shown 
on C. Expression was normalized to the CTRL (indicated as 1 by a 
dashed grey line) and presented as mean ± SEM (n = 3). *p < 0.05, 
**p < 0.01; ***p < 0.001, 1-way ANOVA *(in grey) are significances 
vs CTRL; * (in black) are significances between groups
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we showed that atorvastatin decreased proliferation and 
migration of human vascular endothelial cells in vitro and 
decreases capillary formation in an ex vivo aortic ring 
sprouting assay. These findings are in line with other reports 
in which statins have been shown to have anti-angiogenic 
effects. For instance, a reduction in cell proliferation and 
migration has been associated with a decrease in the produc-
tion of essential signaling proteins in cytoskeleton function 
when cholesterol synthesis was inhibited [47]. Moreover, it 
has been reported that in patients with coronary artery dis-
ease, atorvastatin treatment lowered VEGF expression [48] 
which was also observed in diabetic and non-diabetic rats 
[49]. In addition, tumors treated with simvastatin showed 
lower HIF‐1α and VEGF levels [50].
Another novel aspect of our results relates to the effects 
of atorvastatin on vessel maturation. We and others have pre-
viously shown that neovessels in advanced atherosclerotic 
lesions are structurally vulnerable due to a lack of perycytes 
[17, 51, 52]. Here, we demonstrated that plaque neovessels 
in the HCD and MCD groups are characterized by poor peri-
cyte coverage, in contrast to neovessels in HCD + A group 
which are rich in enveloping pericytes. Subsequent quantifi-
cation demonstrated that atorvastatin significantly decreased 
the % Immature Neovessels in comparison to the MCD and 
HCD group. We further report a dose-dependent increase 
in sprout pericyte coverage in ex vivo mouse cultured aor-
tic rings treated with atorvastatin. The direct association 
between vessel maturity and extravasation of erythrocytes, 
suggesting that neovessel immaturity leads to IPH is a well 
know observation [17, 51, 52]. Accordingly, we detected 
severe areas of IPH in the HCD and MCD groups, but sig-
nificantly less in HCD + A group. Therefore, our findings 
indicate that atorvastatin, independently of its lipid lowering 
effect, reduces intraplaque hemorrhage in ApoE3*Leiden 
mice vein graft lesion by increasing vessel maturation.
Neovessels within advanced atherosclerotic plaques 
exhibit compromised EC integrity characterized by the loss 
of VE-Cad junctions [17]. In our ex vivo cultured mouse 
aortic rings, VE-Cad expression along the sprouts was 
largely increased by treatment with atorvastatin. Previous 
studies have suggested that atorvastatin modulates VE-Cad 
expression by increasing in VE-PTP transcription [53]. 
However, others have shown that VE-PTP knockdown does 
not affect VE-Cad phosphorylation and proteomic analysis 
did not detect VE-PTP associated with the VE-Cad complex 
[54]. Moreover, Src kinase has been pointed out as the main 
implicated mechanism due to its direct association with VE-
Cad [55–57]. In our HUVECs cultures, phosphorylation of 
VE-Cad (Y658) was dose-dependently decreased by atorvas-
tatin, together with its upstream regulator, Src (Y418), when 
compared with the respective controls. Activation of Src and 
the subsequent VE-Cad phosphorylation has been described 
as a critical step in VEGF-induced plasma leakage and its 
regulated by ANGPT1/2-Tie2 signaling [26, 58, 59]. When 
ANGPT1 binds to Tie2 receptor, it promotes VE-Cad accu-
mulation on the endothelial cell surface by Src sequestra-
tion. However, when ANGPT2 is released, it inhibits Tie2-
receptor activation leading to VE-Cad internalization [26]. 
Interestingly, we also demonstrate that atorvastatin inhibits 
ANGPT2 release from ECs restoring its Tie2 activation 
dose-dependently (Fig. 6a–c). However, Tie2 is not exclu-
sively expressed by EC, but also by pericytes [28]. In fact it 
has been shown that ANGPT2 released from ECs inhibits 
Tie2 signaling in pericytes, decreasing Akt, activation [28]. 
Downregulation of the Akt signaling is known to impair 
pericyte coverage as well as promote hemorrhage and leaky 
vessel properties. Therefore, such atorvastatin-mediated 
decrease in ANGPT2 release by EC may explain our in vivo 
and ex vivo findings on pericyte coverage. Both, intraplaque 
neovessels from ApoE3*Leiden mice and sprouts from the 
aortic ring assay, when treated with atorvastatin presented 
increased pericyte coverage. Thus, we suggest that atorv-
astatin increases neovessel stabilization by: (1) inhibiting 
ANGPT2 release from ECs, which (2) restores Tie2-receptor 
activation in EC and pericytes, and consequently, (3) pre-
vents VE-Cad internalization phospho(Y658)-mediated and 
pericyte recruitment inhibition.
Taken together, our findings reveal that atorvastatin 
improves plaque stability by decreasing lesion size and 
inflammation due to their lipid lowering effect. In addi-
tion, atorvastatin also decreases intraplaque angiogenesis 
and intraplaque hemorrhage independent of changes in 
the cholesterol levels of ApoE3*Leiden mice. Added to 
that, atorvastatin increases vessel maturation by improving 
pericyte coverage and increasing VE-Cad expression. In 
conclusion, our findings explains the beneficial pleiotropic 
effects of statins in cardiovascular diseases.
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